Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate.
LeMarbre
G
G
Schinstock
C
C
Hoyer
R
R
Krook
J
J
Tefferi
A
A
D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000188:drug therapy; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007136:Immunoglobulins / Q000008:administration & dosage; D007275:Injections, Intravenous; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011241:Prednisone / Q000008:administration & dosage; D011743:Pyrimidines / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
D001549:Benzamides; D007136:Immunoglobulins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011241:Prednisone